Navigation Links
Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
Date:5/28/2008

ProLindac is currently in a Phase 2 dose-escalating monotherapy trial in recurrent ovarian cancer. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin(TM) or oxaliplatin.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; and Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com .

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing transaction, early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous ri
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related medicine technology :

1. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
2. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
3. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
4. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
5. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
6. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
7. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
8. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
9. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
10. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
11. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)....J., Nov. 21 Ikaria Holdings, Inc....mpany of the Year by the New Jersey Technology Cou...n that provides business support, networking oppor...companies and their leaders. Ikaria earned the awa...nd unique product/service provision. , , "W...
(Date:11/20/2008)... , , PHILADELPHIA, Nov. 20 /PRNewswire-Fi...nounced that the United States Food and Drug Admin...ROMACTA(R) (eltrombopag) for the treatment of thro...pathic) thrombocytopenic purpura (ITP) who have ha...unoglobulins or splenectomy. The approval is a sig...
(Date:11/20/2008)..., Calif., Nov. 20 Bionov...ill present results from the Phase 1B,clinical tr...static breast,cancer, BZL101, at the Society for ...ence in Atlanta, Georgia. The Company,s oral pres...nd will be presented as a part of the Best of the,...
(Date:11/20/2008)...v. 20 PAREXEL Internatio...l biopharmaceutical services provider, today annou... provide regulatory consulting and clinical resear...ice, PAREXEL now has locations throughout five imp... which also include Argentina, Brazil, Chile, and ...
Breaking Medicine Technology:Ikaria(R) Named Private Company of the Year by New Jersey Technology Council 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva 28TM 29 9941 1KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva 28TM 29 9941 2KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva 28TM 29 9941 3KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva 28TM 29 9941 4KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva 28TM 29 9941 5LOGICARE Selects M2SYS Biometric Fingerprint Software to Ensure Patient Privacy and Protect Confidential Information 1988 1LOGICARE Selects M2SYS Biometric Fingerprint Software to Ensure Patient Privacy and Protect Confidential Information 1988 2DNA sensors found to be an effective artificial nose 2696 1Stroke Undertreated 9939 1Stroke Undertreated 9939 2Stroke Undertreated 9939 3
...od and Drug,Administration (FDA) today issued the ...nitiatives/criticalpath/reports/generic.html">Crit... identifying many,of the unanswered scientific que...ions of commonly used drugs. , The report is part ...2004 to discern what challenges exist in moving a,...
...eNeS Pharmaceuticals plc,(LSE: CEN), the Cambridge...that the United States Food and Drug Administratio...(IND) application for the,clinical development of ...he treatment of post-operative pain. Earlier this ... of M6G in Europe in,over 500 patients with post-o...
Other Medicine Technology:New Critical Path Report Highlights Research Needed to Foster,Generic Drug Development 2FDA approves IND on Lead Product M6G 2
(Date:11/21/2008)...als showed Banzel proved effective against Lennox-...althDay News) -- A new drug called Banzel (rufinam...t for a severe form of epilepsy called Lennox-Gast...n announced Friday. , The approval was based on...ded patients ages 4 to 30. Compared to patients wh...
(Date:11/21/2008)...LADELPHIA, Nov. 21 NursingCenter.c...g education and peer reviewed content, has been,u...ts 350,000 registered,users. Powered by Lippincot...now,provides over 900 peer-reviewed continuing ed...cles from more than 50 leading nursing journals.,...
(Date:11/21/2008)...NKLIN LAKES, N.J., Nov. 21 /PRNewswire-FirstCall/ ...for medical intervention in treating 88 percent of...rcent of Americans treated for a chronic condition...pending and 75 percent of all medical costs. A pr...years by Medco Health Solutions, Inc. (NYSE: MHS...
(Date:11/21/2008)...n 430 B.C., a new and deadly diseaseits cause rema...ity-state was teeming with citizens, soldiers and ... Sparta. As streets filled with corpses, social or...ness returned twice and Athens lost a third of its...hens marked the beginning of the end of the Golden...
Breaking Medicine News(10 mins):Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:NursingCenter.com Launches New Features to Improve User Experience 2Health News:NursingCenter.com Launches New Features to Improve User Experience 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6Health News:Study of ancient and modern plagues finds common features 2Health News:Study of ancient and modern plagues finds common features 3Health News:Study of ancient and modern plagues finds common features 4
...confirmed a link between exercising and the preven...a study conducted researchers gathered results fro...0 to 69. Participants were asked about the level o...ent and adult years.Results show women who exercis...
...hat a few alcoholic beverages a month may reduce t...n // with high blood pressure. Researchers found w...ificantly lower risk of death by nearly 30 percent... also a reduced risk of cardiovascular disease dea...
... survival rate of breast cancer patients by 63 per...rd regimes available . The clinical trial strength...mestane, as a first option.// A study showed that ... chance of developing another tumor by 32 percent ...
...lition of Health for Asthmatics in Sports and Exer...ave an exercise test // to 127, 6- to 18-year ol...sk factors were determined by a 10-item questionna...n was a family member having allergies or asthma. ...
Other Medicine News:
...cal IOL is a foldable silicone IOL. It features a ...e inserted with The UNFOLDER® Silver-T Implant... first and only FDA-approved multifocal IOL, and t...nal visionnear, intermediate, and far. The ARRAY&r...
...ferred viscoelastic for phacoemulsification proced...rks from the start to the finish of the case. The ...lastic is the reason. The low to moderate vacuum f...nly a fraction of the viscoelastic agent. However,...
...scoelastic agent for the surgeon who performs cata... Amvisc possesses sufficient viscosity for excelle... is highly cohesive so that complete removal at th...ed. Amvisc is priced to compete with any sodium hy...
...onate (1.8%) viscoelastic solution combines maximu...flo maintains a deep anterior chamber and protects... ideal for routine cataract surgery but can be use...lastic. Combine all these properties with the conv...
Medicine Products: